Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase II clinical study of HLX43 for injection in Australia, a Thursday Hong Kong bourse filing said.
The drug is being tested for the treatment of patients with advanced non-small cell lung cancer.
The phase II study is also ongoing in mainland China and the US.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.